Balasa Dinverno & Foltz’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-1,353
| Closed | -$325K | – | 346 |
|
|
2021
Q4 | $325K | Sell |
1,353
-960
| -42% | -$247K | 0.02% | 257 |
|
|
2021
Q3 | $655K | Buy |
2,313
+3
| +0.1% | +$983 | 0.05% | 167 |
|
|
2021
Q2 | $800K | Sell |
2,310
-880
| -28% | -$267K | 0.06% | 137 |
|
|
2021
Q1 | $892K | Sell |
3,190
-1,227
| -28% | -$331K | 0.07% | 126 |
|
|
2020
Q4 | $1.08M | Sell |
4,417
-2,740
| -38% | -$707K | 0.09% | 98 |
|
|
2020
Q3 | $2.03M | Sell |
7,157
-721
| -9% | -$201K | 0.19% | 48 |
|
|
2020
Q2 | $2.11M | Sell |
7,878
-1,669
| -17% | -$502K | 0.23% | 40 |
|
|
2020
Q1 | $3.02M | Buy |
9,547
+3,431
| +56% | +$1.04M | 0.38% | 30 |
|
|
2019
Q4 | $1.81M | Buy |
6,116
+1,474
| +32% | +$409K | 0.19% | 53 |
|
|
2019
Q3 | $1.08M | Buy |
4,642
+3,698
| +392% | +$861K | 0.13% | 85 |
|
|
2019
Q2 | $221K | Sell |
944
-1,066
| -53% | -$246K | 0.03% | 226 |
|
|
2019
Q1 | $475K | Buy |
2,010
+179
| +10% | +$56.4K | 0.06% | 137 |
|
|
2018
Q4 | $551K | Buy |
1,831
+45
| +3% | +$14.4K | 0.07% | 121 |
|
|
2018
Q3 | $631K | Buy |
1,786
+4
| +0.2% | +$1.38K | 0.07% | 115 |
|
|
2018
Q2 | $517K | Buy |
1,782
+636
| +55% | +$179K | 0.07% | 122 |
|
|
2018
Q1 | $314K | Buy |
1,146
+21
| +2% | +$6.52K | 0.05% | 157 |
|
|
2017
Q4 | $358K | Buy |
1,125
+88
| +8% | +$28.2K | 0.05% | 154 |
|
|
2017
Q3 | $325K | Buy |
1,037
+41
| +4% | +$12.1K | 0.05% | 160 |
|
|
2017
Q2 | $270K | Sell |
996
-86
| -8% | -$22.7K | 0.04% | 172 |
|
|
2017
Q1 | $296K | Buy |
1,082
+45
| +4% | +$12.7K | 0.05% | 160 |
|
|
2016
Q4 | $294K | Buy |
1,037
+160
| +18% | +$47.4K | 0.05% | 145 |
|
|
2016
Q3 | $275K | Sell |
877
-19
| -2% | -$5.63K | 0.05% | 144 |
|
|
2016
Q2 | $217K | Sell |
896
-65
| -7% | -$17.1K | 0.04% | 162 |
|
|
2016
Q1 | $250K | Sell |
961
-70
| -7% | -$18.5K | 0.04% | 148 |
|
|
2015
Q4 | $316K | Buy |
1,031
+22
| +2% | +$6.32K | 0.05% | 146 |
|
|
2015
Q3 | $294K | Sell |
1,009
-69
| -6% | -$22.8K | 0.05% | 141 |
|
|
2015
Q2 | $435K | Sell |
1,078
-19
| -2% | -$7.63K | 0.07% | 103 |
|
|
2015
Q1 | $463K | Buy |
1,097
+39
| +4% | +$15.4K | 0.07% | 91 |
|
|
2014
Q4 | $359K | Sell |
1,058
-10
| -0.9% | -$3.23K | 0.05% | 128 |
|
|
2014
Q3 | $353K | Buy |
1,068
+36
| +3% | +$11.9K | 0.05% | 113 |
|
|
2014
Q2 | $325K | Buy |
1,032
+30
| +3% | +$9.03K | 0.04% | 116 |
|
|
2014
Q1 | $306K | Buy |
1,002
+10
| +1% | +$3.17K | 0.04% | 119 |
|
|
2013
Q4 | $277K | Buy |
992
+10
| +1% | +$2.59K | 0.04% | 120 |
|
|
2013
Q3 | $236K | Buy |
982
+46
| +5% | +$10.3K | 0.04% | 125 |
|
|
2013
Q2 | $201K | Buy |
+936
| New | +$200K | 0.04% | 129 |
|
Other funds holding BIIB
Balasa Dinverno & Foltz's BIIB Position: Q1 2022 in Review
Balasa Dinverno & Foltz sold out of Biogen (BIIB) in Q1 2022, closing a stake of 1,353 shares — an estimated $325K sold.
Balasa Dinverno & Foltz first reported a position in BIIB in Q2 2013 and held it in 35 quarters. The position peaked at $3.02M in Q1 2020. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.
- Balasa Dinverno & Foltz reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
- Balasa Dinverno & Foltz sold 1,353 Biogen shares in Q1 2022, an estimated $325K.
- Balasa Dinverno & Foltz first reported a position in Biogen in Q2 2013 and held it in 35 quarters.
- Balasa Dinverno & Foltz's Biogen position peaked at $3.02M in Q1 2020.
- 952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.
Based on Balasa Dinverno & Foltz's 13F filing for Q1 2022, filed 25 Apr 2022.